KalVista Pharma Appoints New CMO, Director
Ticker: KALV · Form: 8-K · Filed: Mar 7, 2024 · CIK: 1348911
| Field | Detail |
|---|---|
| Company | Kalvista Pharmaceuticals, Inc. (KALV) |
| Form Type | 8-K |
| Filed Date | Mar 7, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $661,800 |
| Sentiment | neutral |
Sentiment: neutral
Topics: personnel-change, board-of-directors, executive-appointment
Related Tickers: KALV
TL;DR
KalVista just hired a new CMO and added a director to the board. Big changes coming?
AI Summary
KalVista Pharmaceuticals, Inc. announced on March 6, 2024, the appointment of Dr. Andrew Hinton as Chief Medical Officer and the election of Dr. Michael Stein as a new Class III director. The company also disclosed compensatory arrangements for its named executive officers. This filing is a current report under Section 13 or 15(d) of the Securities Exchange Act of 1934.
Why It Matters
The appointment of a new Chief Medical Officer and a director signals potential strategic shifts or growth in KalVista's leadership and medical direction.
Risk Assessment
Risk Level: low — This filing is a routine corporate update regarding personnel changes and compensatory arrangements, not indicating significant financial or operational risk.
Key Players & Entities
- KalVista Pharmaceuticals, Inc. (company) — Registrant
- Dr. Andrew Hinton (person) — Appointed Chief Medical Officer
- Dr. Michael Stein (person) — Elected Class III Director
- March 6, 2024 (date) — Date of earliest event reported
FAQ
Who is the new Chief Medical Officer?
Dr. Andrew Hinton has been appointed as the new Chief Medical Officer.
Who was elected as a new director?
Dr. Michael Stein was elected as a new Class III director.
What is the date of the earliest event reported in this 8-K?
The date of the earliest event reported is March 6, 2024.
What type of filing is this?
This is a Current Report on Form 8-K.
What are the key items covered in this 8-K filing?
The filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements of certain officers, Regulation FD Disclosure, and Financial Statements and Exhibits.
Filing Stats: 1,260 words · 5 min read · ~4 pages · Grade level 11.9 · Accepted 2024-03-07 06:38:33
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 Par Value Per Share KALV The Nasdaq
- $661,800 — that provides for a (i) base salary of $661,800 per year, subject to periodic review an
Filing Documents
- d808049d8k.htm (8-K) — 31KB
- d808049dex991.htm (EX-99.1) — 9KB
- 0001193125-24-061344.txt ( ) — 166KB
- kalv-20240306.xsd (EX-101.SCH) — 3KB
- kalv-20240306_lab.xml (EX-101.LAB) — 18KB
- kalv-20240306_pre.xml (EX-101.PRE) — 11KB
- d808049d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description of Exhibit 99.1 Press Release issued March 7, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KALVISTA PHARMACEUTICALS, INC. Date: March 7, 2024 By: /s/ Benjamin L. Palleiko Benjamin L. Palleiko Chief Executive Officer